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ABSTRACT
Objectives: Olanzapine, an antipsychotic agent, exhibits significant antiemetic properties due to its inhibitory activity on neurotransmitters at 
multiple receptors involved in chemotherapy-induced nausea and vomiting (CINV). CINV can have an immensely negative impact on patient’s quality 
of life (QOL) and daily activities. Our objectives were to determine the effectiveness of adding olanzapine to standard antiemetic regimens for the 
prevention of CINV in cancer patients and to compare the QOL of such patients with those receiving standard antiemetic regimens.
Methods: A prospective, observational, cohort study was done on patients receiving either highly or moderately emetogenic chemotherapy (MEC). 
The patients who received only the standard antiemetic regimens were considered as the control group and those who received 10 mg of olanzapine 
once daily on days 1-5 of chemotherapy in addition to the standard antiemetic regimens were considered to be the study group. The patients were 
assessed for grades of nausea and vomiting using National Cancer Institute common terminology criteria for adverse events and for QOL using 
European Organization in Research and Treatment of Cancer QOL questionnaire.
Results: Patients were evaluated for a total of 168 cycles of chemotherapy. Compared to the control group, the study group patients showed significant 
improvement in response to acute nausea (p=0.02) but not in acute vomiting (p=0.09). However, response to delayed nausea and vomiting improved 
significantly (p=0.004 and p=0.05, respectively). The QOL of study group patients showed significant improvement in functional scales and symptom 
scales (p<0.02). Global health status also increased significantly (p=0.02) in the study group patients.
Conclusion: Olanzapine containing pre-medication regimens can reduce acute and delayed nausea and delayed vomiting and improve the QOL of 
cancer patients receiving highly or moderately emetogenic chemotherapeutic agents as compared to the standard pre-medication regimens.
Keywords: Adverse events, Chemotherapy-induced nausea and vomiting, Effectiveness, Olanzapine, Quality of life.
INTRODUCTION
Chemotherapy-induced nausea and vomiting (CINV) are severe 
distressing adverse effects experienced by cancer patients receiving 
chemotherapy. Nausea and vomiting associated with cancer 
chemotherapy is distinct from typical nausea and vomiting that 
many people experience in their normal daily life. CINV can have an 
immensely negative impact on the patients’ quality of life (QOL) and 
daily activities [1-5]. It can have a number of clinical implications for 
patients, including non-compliance with treatment, unwillingness or 
inability to eat and/or drink, and nutritional deficits. In most of the 
cases, sufferings experienced by cancer patients have been related to 
QOL to a great extent, and hence measurement of QOL can be used as an 
outcome measure to compare the effectiveness of different antiemetic 
treatment regimens [6,7].
The goal of antiemetic therapy is to reduce or negate nausea and vomiting 
associated with chemotherapy. A number of antiemetic regimens exist 
but are not fully effective. The most commonly used antiemetics such 
as 5-hydroxytryptamine-3 (5HT3) antagonists, dexamethasone, or 
neurokinin-1 receptor antagonists prevent emesis only in 60-70% of 
cancer patients receiving highly emetogenic chemotherapy (HEC) [8,9]. 
Hence, new drugs and regimens are being explored for more effective 
control of nausea and vomiting. Olanzapine in lieu of its inhibitory 
activity on neurotransmitters at multiple receptors involved in CINV, 
especially at D2 and 5-HT3 receptors, may exhibit significant antiemetic 
properties [10-12]. Hence, addition of olanzapine to standard antiemetic 
regimens may improve control of nausea and vomiting in cancer 
patients receiving highly or moderately emetogenic chemotherapeutic 
agents. As a result of the reduction in nausea and vomiting, the QOL of 
the patients may improve [7]. Improved QOL during chemotherapy is 
bound to increase the confidence of the patients, improve compliance 
to treatment, and ultimately result in better clinical efficacy. Often, 
the cancer patients have some symptoms of depression and anxiety, 
and olanzapine can also exert an antidepressant effect in these 
patients [13,14]. Although there are studies [15-20] describing the use 
of olanzapine for prevention of CINV, there is scarcity of data on Indian 
patients. Hence, our study was undertaken to compare the effectiveness 
of olanzapine containing antiemetic regimens with standard regimens 
for the prevention of CINV and to compare the QOL of patients between 
the two groups.
METHODS
A prospective observational study was carried out on cancer patients 
receiving highly or moderately emetogenic chemotherapy at the 
Department of Medical Oncology and Hematology of Amrita Institute 
of Medical Sciences and Research Centre, Kochi, India, from October 
2013 to June 2014. This study was approved by the Institutional Review 
Board, and informed signed consent was obtained from all the study 
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participants. Chemotherapy-naïve patients aged 18-65 years receiving 
treatment with highly or moderately emetogenic chemotherapeutic 
drugs and no known hypersensitivity to olanzapine or 5-HT3 receptor 
antagonists were included. Patients on treatment with an antipsychotic 
agent or with a known history of psychiatric disease, diabetes, or 
those receiving minimal to low-risk emetogenic chemotherapeutic 
drugs were excluded from the study. Patients on concurrent or prior 
abdominal radiation therapy were also excluded. The use of olanzapine 
was at the discretion of the treating physicians, which is the routine 
practice in the department.
The European Organization in Research and Treatment of Cancer 
QOL Questionnaire (EORTC QOL) version 3.0 [21-24] was used 
for the assessment of QOL and Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0 [25] was used to grade nausea 
and vomiting. As per the CTCAE guidelines, the severity of nausea is 
ranked into three grades (1-3) and vomiting into five grades (1-5) with 
increasing severity.
The study patients who received the first cycle of chemotherapy 
with highly or moderately emetogenic agents were provided with 
EORTC QOL questionnaire in the language of their choice (Malayalam 
or English) and a form for assessment of acute and delayed CINV. 
These were collected back during the second cycle and they were 
provided with fresh QOL questionnaire and forms. This was repeated 
for a total of four cycles. The pre-medications and the chemotherapy 
regimens given to the patients were blinded to the investigators until 
all the four cycles of chemotherapy, and data collection on grades 
of nausea and vomiting and QOL of patients were completed. All the 
patients who received 10 mg of olanzapine once daily orally on days 
1-5 along with standard antiemetic regimens were included in the 
study group (olanzapine arm), whereas the control group patients 
consisted of those receiving antiemetic regimens without olanzapine. 
The standard antiemetic regimen consisted of ondansetron 16 mg or 
palonosetron 0.25 mg in combination with dexamethasone 8-12 mg. 
Chemotherapeutic regimens received by the study group patients 
were matched with those of the control group patients. For this, the 
patients in the control group were stratified into 6 groups based on the 
six chemotherapy combinations received by the study group patients. 
A number of patients equal to the study group taking these six types 
of chemotherapy regimens were chosen by random sampling of the 
124 patients who received only the standard antiemetic regimens to 
form the control group. The scores for EORTC QOL questionnaire were 
calculated and analyzed. Nausea or vomiting occurring in ≤ 24 hrs of 
chemotherapy was designated as acute while those occurring within 
25-120 hrs were considered delayed occurrence [26,27]. Patients were 
also asked to report other adverse effects such as sedation, increase 
in appetite, or occurrence of any other untoward effects. After the 
chemotherapy, patients were also monitored for body weight and 
laboratory parameters such as fasting blood glucose levels and lipid 
profiles. The outcome of treatment was evaluated by comparing the 
percentage of total chemotherapy cycles in which the patients were 
free of nausea and vomiting and in which the patients had high QOL 
in the study and control groups. The secondary end point for outcome 
evaluation was attainment of complete response which was defined as 
no emesis and no use of rescue medications during the acute, delayed, 
or the overall period of 0-120 hrs after chemotherapy during each cycle 
of therapy.
The collected data were compiled using Microsoft Excel and analyzed 
using Statistical Package for the Social Sciences software version 20. 
Descriptive statistical parameters were calculated and significance of 
the study results was assessed by independent t-test.
RESULTS
A total of 145 eligible patients completed 4 cycles of chemotherapy 
during the study period. Only 21 patients were found to have received 
the pre-medication regimen containing olanzapine and they were 
included in the study group. Hence, an equal number of patients 
receiving similar chemotherapy as the study group but with the pre-
medication regimens without olanzapine were identified from the 
remaining 124 patients. The control and study group patients each 
completed 84 cycles of chemotherapy. Majority of patients in both 
groups (38.1% in control group vs. 33.3% in the study group) received 
palonosetron 0.25 mg in combination with dexamethasone 12 mg and 
remaining received ondansetron 16 mg with dexamethasone 8 mg. Both 
the control and study group patients were also comparable (p>0.05) 
with respect to age, gender, and chemotherapy regimens received 
(Table 1). Majority of patients receiving chemotherapy in the control 
group and study group was in the age range 45-62 years.
Table 2 describes the distribution of chemotherapy cycles of patients 
experiencing acute or delayed nausea after chemotherapy. The study 
group patients were free of both acute and delayed nausea in 64.3% of 
cycles in comparison to 13.1% in the control group (p=0.003). Similarly, 
there was a significant increase in the number of patients free of both 
acute and delayed vomiting in the study group (Table 3).
Only 1.44% of patients experienced Grade 1 nausea in study group, 
whereas 17.4% of patients suffered Grade 1 nausea in the control 
group (p=0.003). Grade 2 nausea was experienced by 13.9% of patients 
in study group and 85.9% of patients in the control group (p=0.019). 
The control group had 0.24% of patients experiencing Grade 3 nausea, 
but none of the patients in the study group reported the same (Fig. 1). 
About 96.4% of patients in the study group were free of vomiting in 
comparison to 71.4% of the control group (p=0.015) (Fig. 2). Complete 
control of nausea in the acute phase, delayed phase, and overall period 
of 0-120 hrs was achieved in 94%, 65.5%, and 64.3% of chemotherapy 
cycles, respectively, in the olanzapine arm against 76.1%, 15.5%, and 
11% in the control arm.
The QOL of patients was assessed in all the 168 cycles of chemotherapy. 
Significant improvement in QOL was observed in the study group 
patients in the domains of physical functioning (p<0.0001), role 
functioning (p=0.005), and emotional functioning (p=0.0005) as 
compared to the control group patients (Fig. 3). The study group 
patients exhibited significant improvement in symptom scales such 
as constipation (p=0.009), nausea and vomiting (p<0.0001), dyspnea 
Fig. 1: Mean percentage of chemotherapy cycles with various 
grades of nausea in the control and study group patients. aGrade 0 
denotes patients free of nausea
Fig. 2: Mean percentage of chemotherapy cycles with various 
grades of vomiting in the control ad study group patients. 
aGrade 0 denotes patients free of vomiting
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(p=0.009), insomnia (p=0.009), and appetite loss (p=0.001) as 
compared to control group patients (Fig. 4). There was also significant 
improvement in global health status for the study group patients 
(p=0.01) in comparison to control group patients.
None of the patients reported any side effect with the use of olanzapine 
during the four cycles of chemotherapy except for dyspepsia by five 
patients and dry mouth by six patients in the olanzapine arm and four 
patients in the control arm. Twelve patients in the olanzapine arm 
reported improvement in appetite. None of the patients reported any 
sedation with the use of olanzapine. Similarly, none of the patients in 
either group had hyperglycemia.
DISCUSSION
The present study evaluated QOL and control of nausea and vomiting 
in cancer patients who were given olanzapine in addition to the 
standard antiemetic regimens before highly or moderately emetogenic 
chemotherapy. Adding olanzapine to the standard antiemetic regimen 
consisting of a 5-HT3 antagonist, and dexamethasone was more 
effective than the standard regimen for the prevention of Grade 1 and 
Table 1: Baseline characteristics of the study patients
Parameters Control group (n=21) Study group (n=21)
Mean age (years)±SD 54.9±7.98 51.4±10.19
Median age (years) 53.0 51.0
% of males/females 14.3/85.7 14.3/85.7
% of patients receiving HECa 85.7 85.7
% of patients receiving MECb 14.3 14.3
Cancer type (% of patients)
Breast cancer 61.8 61.8
Ovarian cancer 14.3 4.8
Stomach cancer 9.5 9.5
Others 14.4 23.9
Number (%) of patients receiving various chemotherapy regimens
Doxorubicin (60 mg/m2)+cyclophosphamide (600 mg/m2) 13 (61.8) 13 (61.8)
Carboplatin (AUC 6 mg/hr/ml) 1 (4.8) 1 (4.8)
Cisplatin (75-100 mg/m2) 2 (9.5) 2 (9.5)
Cisplatin (75 mg/m2)+etoposide (100 mg/m2) 1 (4.8) 1 (4.8)
Epirubicin (50 mg/m2)+oxaliplatin (130 mg/m2) 1 (4.8) 1 (4.8)
Paclitaxel (175 mg/m2)+carboplatin (AUC 6 mg/hr/ml) 3 (14.3) 3 (14.3)
aHEC: Highly emetogenic chemotherapy, bMEC: Moderately emetogenic chemotherapy, SD: Standard deviation
Table 2: Comparison of chemotherapy cycles of control and study group patients exhibiting nausea during 168 cycles of chemotherapy
aType of nausea Control group (n=84 cycles)
No. (mean % cycles±SD)
Study group (n=84 cycles)
No. (mean % cycles±SD)
p value (independent t‑test)
Acute 20 (23.8±10.3) 5 (6.0±6.0) 0.024
Delayed 71 (84.5±8.1) 29 (34.5±20.7) 0.004
Acute+delayed 19 (22.6±8.1) 3 (3.6±2.4) 0.004
Free of both Acute+delayed 11 (13.1±7.1) 54 (64.3±20.0) 0.003
aSome patients experienced more than one episode during a chemotherapy cycle. SD: Standard deviation
Table 3: Comparison of chemotherapy cycles of control and study group patients exhibiting vomiting during 168 cycles of chemotherapy
aType of vomiting No. (mean % cycles±SD) p value (independent t‑test)
Control group (n=84 cycles) Study group (n=84 cycles)
Acute 5 (6.0±6.0) 0 (0±0) 0.093
Delayed 24 (40.5±17.6) 13 (15.5±10.5) 0.051
Acute+delayed 14 (16.7±6.4) 0 (0±0) 0.264
No acute/delayed 31 (48.8±4.6) 70 (83.3±12.3) 0.002
aSome patients experienced more than one episode during a chemotherapy cycle. SD: Standard deviation
Fig. 3: Percentage of chemotherapy cycles with high quality of 
life in both control and study group patients showing functional 
scales and global health status
Fig. 4: Percentage of chemotherapy cycles with high quality of 
life in control and study group patients with respect to symptom 
scales
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Grade 2 nausea or vomiting. Chemotherapy cycles free of both acute 
and delayed nausea were significantly more in the olanzapine arm than 
the control arm. The QOL of the patients in the olanzapine arm showed 
significant improvement in scores of functional scales such as physical, 
emotional, role and cognitive functioning, and symptom scales such as 
nausea and vomiting, dyspnea, insomnia, and appetite loss as compared 
to those receiving standard antiemetic regimens without olanzapine. 
Addition of olanzapine also resulted in significant improvement in 
global health status of the patients. Majority of the patients were free of 
any adverse effects with the use of olanzapine.
Previous studies [15-20] have shown the efficacy of olanzapine for the 
prevention of CINV when used in combination with standard antiemetic 
regimens. A recent phase three trial [28] studied the effect of combining 
olanzapine with a three drug regimen of dexamethasone, aprepitant or 
fosaprepitant, and a 5-HT3 receptor antagonist for the prevention of nausea 
and vomiting in chemotherapy-naïve patients taking HEC. The proportion 
of patients with no chemotherapy-induced nausea in the olanzapine arm 
was significantly higher in the first 24 hrs after chemotherapy, the period 
from 25 to 120 hrs after chemotherapy, and the overall 120-hr period 
post-chemotherapy. However, in our study, olanzapine was added to a 
regimen consisting of two drugs, namely, dexamethasone and a 5-HT3 
receptor antagonist only. Moreover, that study evaluated the efficacy 
of olanzapine only for the first cycle of chemotherapy, whereas in our 
study, the overall effectiveness of olanzapine was evaluated for all the 
four cycles of chemotherapy. Patients in the olanzapine arm were free of 
both acute and delayed nausea in 64.3% (54/84) of chemotherapy cycles, 
whereas for patients of the control arm, this was achieved only in 13.1% 
(11/84) of cycles in our study.
Achievement of better control of nausea and vomiting with the use 
of olanzapine in the absence of aprepitant is a cost-effective strategy 
for patients of the developing countries in resource poor settings who 
cannot afford expensive antiemetics such as aprepitant. Olanzapine, 
an atypical antipsychotic, was approved by the US Food and Drug 
Administration (FDA) in 1996 for the treatment of schizophrenia 
and bipolar disorder and generic versions of the drug are available 
since 2011 and are inexpensive. Olanzapine acts on multiple 
neurotransmitters [10-12] blocking the action of serotonin at 5H2a, 
5H2c, 5H3, and 5HT6 receptors, dopamine at D1, D2, D3, and D4 brain 
receptors, catecholamines at alpha 1 adrenergic receptors, acetylcholine 
at muscarinic receptors (m1, m2, m3, and m4), and histamine at H1 
receptors. The action of olanzapine, especially at D2, 5-HT2c, and 5-HT3 
receptors which are involved in mediation of nausea and vomiting 
makes it a good candidate for control of CINV. It is effective for both 
acute and delayed CINV due to its action at multiple neurotransmitters. 
The long half-life (21-54 hrs) of olanzapine [29] permits once daily 
dosing and may contribute to increased patient compliance. A Phase II 
study [16] also showed that olanzapine combined with a single dose of 
dexamethasone, and a single dose of palonosetron was very effective in 
controlling acute and delayed CINV in patients receiving both HEC and 
MEC. A recent study [30] evaluated the efficacy, safety, and cost benefit 
of olanzapine as compared to aprepitant for the prevention of CINV 
in patients receiving palonosetron and dexamethasone combination 
regimens. There was no difference in safety and efficacy but olanzapine 
was a cost-effective alternative to aprepitant.
In both the control as well as olanzapine arms, 85% of our patients 
were females. 33.3% (7/21) and 47.6% (10/21), respectively, of the 
patients were below 50 years of age. Both female gender [31] and age 
<50 years [32] are risk factors for CINV. Although the HEC drug cisplatin 
was administered only to 14.3% of patients in both arms, 61.8% of 
patients in both the arms received a combination of doxorubicin and 
cyclophosphamide. Administered individually, cyclophosphamide 
(<1500 mg/m2) and doxorubicin are only moderately emetogenic, but 
their combination is considered highly emetogenic [33], especially in 
women with breast cancer [34] and 61.8% of our patients were treated 
for cancer of the breast. Hence, majority of our patients (86.3%) 
received HEC. The remaining had MEC.
In all the four cycles of chemotherapy from day 1-5 taken together, 
significantly more number of patients in the study group were free 
from nausea as compared to the control group patients. There were 
no patients with Grade 3 nausea in the study group and only a few 
patients (5/84) in control group. There was a significant decrease in 
the number of patients with Grade 1 and 2 nausea in the study group 
as compared to the control group patients. Grade 3 and 4 vomiting 
were absent in the entire cohort of patients. In all the 84 cycles of 
chemotherapy taken together, there was a significant decrease in the 
number of patients with vomiting in the study group as compared 
to the control group. Similarly, there was significant increase in the 
number of patients free of vomiting in the study group as compared to 
the control group patients.
The EORTC QOL questionnaire is a structured tool with 30 questions 
designed for heterogeneous group of cancer patients. The QLQ-C30 
is composed of five functional scales, three symptom scales (fatigue, 
pain, and nausea), a global health status scale, and six single items 
which describe cancer-oriented symptoms. All of the scales and 
single-item measures range in score from 0 to 100. A high score 
represents a higher response level. Thus, a high score for a functional 
scale represents a high/healthy level of functioning, a high score 
(ranging 50-100) for the global health status represents a high QOL, 
but a high score (50-100 score) for a symptom scale/item represents 
a high level of symptomatology/problems [23]. A decreased score 
for any of the symptom scales represents an improvement of 
symptomatic problem.
Prevention of CINV can improve cancer patient’s QOL and activities of 
daily living. Delayed CINV can severely impair the QOL of patients [1]. 
The overall assessment of QOL after chemotherapy of the study patients 
showed a significant improvement in scores of functional scales such 
as physical, emotional, role and cognitive functioning, and symptom 
scales such as nausea and vomiting, dyspnea, insomnia, appetite loss. 
The Global Health Status also increased significantly. A study [15] by 
Tan et al. also found significant improvement in global health status, 
social functioning, fatigue, nausea and vomiting, insomnia, and appetite 
loss in patients receiving a three drug regimen consisting of azasetron, 
dexamethasone, and olanzapine for the prevention of CINV due to HEC 
or MEC. But in our study, with respect to social functioning and fatigue, 
there was no improvement in QOL scores.
In a phase three trial [28] by Navari et al., some patients who received 
olanzapine experienced tiredness and sedation, especially on the second 
day which resolved with continued use of the drug in subsequent days. 
However, none of the 21 patients in our study reported any adverse 
effect of sedation with the use of olanzapine during the 4 cycles of 
chemotherapy, but five patients reported dyspepsia and dry mouth by 
six patients. Other side effects of olanzapine such as diabetes [35] and 
weight gain [36,37] may not be evident with the short-term use of the 
drug. Drug reaction with eosinophilia and systemic symptoms (DRESS) 
has been recently added by the US FDA [38] as a warning sign to the drug 
label of olanzapine. DRESS is a rare but serious skin reaction, and the 
patients develop fever with a rash and swollen lymph glands or swelling 
in the face. However, our patients were free of DRESS syndrome.
The small sample size is a limitation of our study. The effectiveness 
of olanzapine for control of nausea and vomiting caused by radiation 
therapy to the brain, upper abdomen, or due to total body radiation 
therapy as in stem cell transplants or when chemotherapy is given 
along with radiation can be explored in the future.
CONCLUSION
Addition of olanzapine to standard antiemetic regimen of 
dexamethasone and a 5-HT3 receptor antagonist can improve control of 
nausea and vomiting and at the same time improve the QOL of patients 
receiving highly or moderately emetogenic chemotherapeutic agents 
as compared to patients receiving standard pre-medication regimens 
without olanzapine.
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